Acer Therapeutics Inc.

Acer Therapeutics Inc. is a pharmaceutical company specializing in the acquisition, development, and commercialization of therapies for rare and life-threatening diseases. The company's pipeline includes EDSIVO for vascular Ehlers-Danlos Syndrome, ACER-001 for inborn errors of metabolism, ACER-801 for Vasomotor Symptoms, and ACER-2820 for infectious diseases, including COVID-19. Acer generates revenue through the development and commercialization of these clinical-stage candidates, as well as through research collaborations and license agreements with organizations such as the National Center for Advancing Translational Sciences and Sanofi.

Products

• EDSIVO

• ACER-001

• ACER-801

• ACER-2820